What You Should Know:
– Cedar Gate Technologies (Cedar Gate), a leader in value-based care technology, announced today the potential for significant healthcare cost savings through early identification of at-risk patients.
– An analysis of their national Healthcare Benchmark Database, encompassing nearly 13 million member lives, revealed a staggering $1.4 billion in potential savings.
Machine Learning for Early Disease Detection
Cedar Gate’s platform leverages machine learning models to pinpoint individuals with a high risk of developing coronary artery disease (CAD) and congestive heart failure (CHF). This allows for earlier intervention, potentially preventing costly and debilitating events. According to a National Institutes of Health (NIH) study, patients with CAD experiencing a major cardiac event face an additional $44,495 in healthcare costs within a year. Cedar Gate’s model identified over 24,000 individuals in its database at high risk for CAD but currently undiagnosed. Early intervention for this population has the potential to save nearly $1.1 billion.
Targeting Heart Failure and Hospital Admissions
Congestive heart failure is a major healthcare burden, accounting for over 1 million hospitalizations annually in the US and Europe, with associated costs exceeding $18 billion. Cedar Gate’s model identified over 17,000 undiagnosed members at risk for CHF in its database. Early intervention could potentially save $307.4 million or more by preventing hospitalizations.
How Cedar Gate’s Technology Works
Cedar Gate’s machine learning algorithms rely on a proprietary risk scoring system, analyzing various metrics beyond traditional thresholds to identify individuals at high risk for chronic diseases. This comprehensive approach is continually refined through collaboration between data scientists and a dedicated clinical team.
Validation and Accuracy
To assess the model’s effectiveness, Cedar Gate employed the Matthews Correlation Coefficient (MCC), a metric indicating the strength of positive correlation. The model scored an impressive 0.80, demonstrating a high degree of accuracy in predicting CAD and CHF risk.
“Our AI-powered predictive models enable interventions, diagnoses, and treatments that can reduce risk and slow chronic disease progression on a large scale,” said David B. Snow Jr., Chairman and CEO of Cedar Gate. “Preventive care and early intervention are at the center of effective value-based care. By leveraging our team of analytics experts and vast anonymized member data, we’re advancing technology that helps providers and payers optimize outcomes, lower costs, and close gaps in care.”
